BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration
In conclusion, BLU-5937 was selected as a drug candidate for the treatment of chronic cough due to its high potency and selectivity for P2X3 homotrimeric receptors, strong anti-tussive effects, excellent tolerability and predicted pharmacokinetic properties in humans.
Source: Pulmonary Pharmacology and Therapeutics - Category: Respiratory Medicine Source Type: research
More News: Brain | Cough | Drugs & Pharmacology | Ganglions | Guinea Health | Neurology | Reflex Sympathetic Dystrophy | Respiratory Medicine | Study